Literature DB >> 20501855

Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation.

Lorenzo Montanaro1, Maria Calienni, Sara Bertoni, Laura Rocchi, Pasquale Sansone, Gianluca Storci, Donatella Santini, Claudio Ceccarelli, Mario Taffurelli, Domenica Carnicelli, Maurizio Brigotti, Massimiliano Bonafè, Davide Treré, Massimo Derenzini.   

Abstract

In up to 60% of human cancers, p53 gene mutations are responsible for direct inactivation of the tumor suppressor function of p53. Alternative mechanisms of p53 inactivation described thus far mainly affect its posttranslational regulation. In X-linked dyskeratosis congenita, a multisystemic syndrome characterized by increased cancer susceptibility, mutations of the DKC1 gene encoding dyskerin cause a selective defect in the translation of a subgroup of internal ribosome entry site (IRES)-containing cellular mRNAs. In this study, we show that impairment of dyskerin function can cause p53 inactivation due to a defect in p53 mRNA translation. siRNA-mediated reduction of dyskerin levels caused a decrease of p53 mRNA translation, protein levels, and functional activity, both in human breast cancer cells and in primary mammary epithelial progenitor cells. These effects seemed to be independent of the known role of dyskerin in telomerase function, and they were associated with a specific impairment of translation initiation mediated by IRES elements present in p53 mRNA. In a series of human primary breast cancers retaining wild-type p53, we found that low levels of dyskerin expression were associated with reduced expression of p53-positive target genes. Our findings suggest that a dyskerin-mediated mechanism of p53 inactivation may occur in a subset of human tumors. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501855     DOI: 10.1158/0008-5472.CAN-09-4024

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Small RNAs with big implications: new insights into H/ACA snoRNA function and their role in human disease.

Authors:  Mary McMahon; Adrian Contreras; Davide Ruggero
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-10-31       Impact factor: 9.957

Review 2.  Specialized ribosomes: a new frontier in gene regulation and organismal biology.

Authors:  Shifeng Xue; Maria Barna
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-23       Impact factor: 94.444

Review 3.  An emerging role for the ribosome as a nexus for post-translational modifications.

Authors:  Deniz Simsek; Maria Barna
Journal:  Curr Opin Cell Biol       Date:  2017-04-23       Impact factor: 8.382

4.  Dyskerin is required for tumor cell growth through mechanisms that are independent of its role in telomerase and only partially related to its function in precursor rRNA processing.

Authors:  Faizan Alawi; Ping Lin
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

5.  Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Authors:  Marie-Jo Halaby; Benjamin R E Harris; W Keith Miskimins; Margot P Cleary; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

Review 6.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

7.  RNA modifications and cancer.

Authors:  Phensinee Haruehanroengra; Ya Ying Zheng; Yubin Zhou; Yun Huang; Jia Sheng
Journal:  RNA Biol       Date:  2020-02-07       Impact factor: 4.652

Review 8.  Role of RNA modifications in cancer.

Authors:  Isaia Barbieri; Tony Kouzarides
Journal:  Nat Rev Cancer       Date:  2020-04-16       Impact factor: 60.716

9.  H/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation.

Authors:  Cristian Bellodi; Mary McMahon; Adrian Contreras; Dayle Juliano; Noam Kopmar; Tomoka Nakamura; David Maltby; Alma Burlingame; Sharon A Savage; Akiko Shimamura; Davide Ruggero
Journal:  Cell Rep       Date:  2013-05-23       Impact factor: 9.423

Review 10.  New prospects for targeting telomerase beyond the telomere.

Authors:  Greg M Arndt; Karen L MacKenzie
Journal:  Nat Rev Cancer       Date:  2016-06-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.